Drugs / AZD2066
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT00930306 | Jun → Sep 2009 | chronic pain syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00829088 | Jan → Feb 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00766012 | Sep 2008 → Jul 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00686504 | Apr → Jun 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00690404 | Apr → Jun 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00684502 | Jan → Nov 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00813306 | Dec 2008 → Nov 2009 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01145755 | May → Nov 2010 | major depressive disorder | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT00939094 | Aug 2009 → Nov 2010 | myofascial pain syndrome, neuropathy, painful | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT00857623 | Feb → Aug 2009 | diabetic neuropathy | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2066 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01145755 ↗ |
| Modality | Small molecule | — CHEMBL3545164 ↗ |
| Route | Oral | “Oral solution administered orally once per day on day 1, and then day 3 through to day 12.” NCT00684502 ↗ |
| Target | GRM5 | “Metabotropic glutamate receptor 5 modulator” CHEMBL3545164 ↗ |